Testing ZV0203 for HER2-positive advanced solid tumors
Part of Cancer clinical trials.
This Phase 1 study tests ZV0203, a new investigational treatment, in people with HER2-positive advanced or metastatic solid tumors that cannot be removed and have not responded to standard treatment. The goal is to find a safe dose and see how the disease responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older, and you can sign consent papers.
- Your tumor is HER2-positive from prior testing (HER2 on the tumor tissue).
- Your cancer is advanced or metastatic, not removable by surgery, and you’ve run out of standard treatment options (or couldn’t tolerate them).
- You’re able to function fairly well (ECOG performance status 0 or 1).
- Heart function is strong enough (left ventricular ejection fraction at least 50% on echo/MUGA).
- Your blood counts and major organs (kidney, liver, etc.) meet lab safety levels, checked within about 14 days of starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests DB-1303 and BNT323 together in people with advanced or metastatic solid cancers that have specific HER2 features. It may be an option when standard treatments have stopped working, aiming to find a safer dose and early signs of effectiveness.
This trial tests a new drug called ZE94-0605 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it is safe and can shrink tumors.
This Phase 1 trial tests D3L-001 alone in people with HER2-positive advanced solid tumors. It’s mainly looking to see how the drug works and how safe it is in this group.
This trial tests a new combination treatment for people with advanced solid tumors that have HER2 changes. The goal is to see if it can shrink tumors or slow growth.
This trial tests a new drug, AVZO-023, alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if it can shrink tumors or slow their growth.
This trial tests a new drug, CAN016, for people with advanced solid tumors that have HER2 expression or a HER2 gene change. You may qualify if your cancer has gotten worse after trying other HER2-targeted treatments.
Hear when a new HER2-positive Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.